ESR1 and breast carcinoma: The association between ever-use of OC and estrogen receptor-negative (ER-) breast cancer as compared with ER+ cancer, however, is less clear; with a number of past studies reporting strong associations [32–36], and other studies concluding little or no difference [37–42].